vs

Side-by-side financial comparison of HUTCHMED (China) Ltd (HCM) and Tempus AI, Inc. (TEM). Click either name above to swap in a different company.

Tempus AI, Inc. is the larger business by last-quarter revenue ($367.2M vs $270.8M, roughly 1.4× HUTCHMED (China) Ltd). HUTCHMED (China) Ltd runs the higher net margin — 0.7% vs -14.8%, a 15.5% gap on every dollar of revenue. On growth, Tempus AI, Inc. posted the faster year-over-year revenue change (83.0% vs -16.5%). HUTCHMED (China) Ltd produced more free cash flow last quarter ($3.4M vs $-41.5M).

HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.

Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."

HCM vs TEM — Head-to-Head

Bigger by revenue
TEM
TEM
1.4× larger
TEM
$367.2M
$270.8M
HCM
Growing faster (revenue YoY)
TEM
TEM
+99.5% gap
TEM
83.0%
-16.5%
HCM
Higher net margin
HCM
HCM
15.5% more per $
HCM
0.7%
-14.8%
TEM
More free cash flow
HCM
HCM
$44.9M more FCF
HCM
$3.4M
$-41.5M
TEM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCM
HCM
TEM
TEM
Revenue
$270.8M
$367.2M
Net Profit
$2.0M
$-54.2M
Gross Margin
37.7%
Operating Margin
-13.2%
-16.7%
Net Margin
0.7%
-14.8%
Revenue YoY
-16.5%
83.0%
Net Profit YoY
-83.6%
-316.2%
EPS (diluted)
$0.00
$-0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCM
HCM
TEM
TEM
Q4 25
$270.8M
$367.2M
Q3 25
$334.2M
Q2 25
$277.7M
$314.6M
Q1 25
$324.5M
$255.7M
Q4 24
$200.7M
Q3 24
$180.9M
Q2 24
$305.7M
$166.0M
Q1 24
$145.8M
Net Profit
HCM
HCM
TEM
TEM
Q4 25
$2.0M
$-54.2M
Q3 25
$-80.0M
Q2 25
$455.0M
$-42.8M
Q1 25
$11.9M
$-68.0M
Q4 24
$-13.0M
Q3 24
$-75.8M
Q2 24
$25.8M
$-552.2M
Q1 24
$-64.7M
Gross Margin
HCM
HCM
TEM
TEM
Q4 25
37.7%
Q3 25
Q2 25
0.1%
Q1 25
48.0%
Q4 24
Q3 24
Q2 24
41.1%
Q1 24
Operating Margin
HCM
HCM
TEM
TEM
Q4 25
-13.2%
-16.7%
Q3 25
-18.3%
Q2 25
-1.3%
-19.6%
Q1 25
-5.0%
-26.9%
Q4 24
-25.3%
Q3 24
-29.6%
Q2 24
-9.0%
-321.4%
Q1 24
-36.5%
Net Margin
HCM
HCM
TEM
TEM
Q4 25
0.7%
-14.8%
Q3 25
-23.9%
Q2 25
163.8%
-13.6%
Q1 25
3.7%
-26.6%
Q4 24
-6.5%
Q3 24
-41.9%
Q2 24
8.4%
-332.7%
Q1 24
-44.4%
EPS (diluted)
HCM
HCM
TEM
TEM
Q4 25
$0.00
$-0.30
Q3 25
$-0.46
Q2 25
$0.52
$-0.25
Q1 25
$0.01
$-0.40
Q4 24
$2.56
Q3 24
$-0.46
Q2 24
$0.03
$-6.86
Q1 24
$-1.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCM
HCM
TEM
TEM
Cash + ST InvestmentsLiquidity on hand
$1.4B
$604.8M
Total DebtLower is stronger
$93.2M
Stockholders' EquityBook value
$1.2B
$491.3M
Total Assets
$1.8B
$2.3B
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCM
HCM
TEM
TEM
Q4 25
$1.4B
$604.8M
Q3 25
$655.9M
Q2 25
$1.4B
$186.3M
Q1 25
$836.1M
$151.6M
Q4 24
$341.0M
Q3 24
$388.0M
Q2 24
$802.5M
$478.8M
Q1 24
$79.9M
Total Debt
HCM
HCM
TEM
TEM
Q4 25
$93.2M
Q3 25
Q2 25
$93.4M
Q1 25
$82.8M
Q4 24
Q3 24
Q2 24
$82.1M
Q1 24
Stockholders' Equity
HCM
HCM
TEM
TEM
Q4 25
$1.2B
$491.3M
Q3 25
$507.8M
Q2 25
$1.2B
$309.6M
Q1 25
$759.9M
$326.2M
Q4 24
$56.3M
Q3 24
$53.7M
Q2 24
$740.1M
$98.3M
Q1 24
$-1.5B
Total Assets
HCM
HCM
TEM
TEM
Q4 25
$1.8B
$2.3B
Q3 25
$2.3B
Q2 25
$1.8B
$1.6B
Q1 25
$1.3B
$1.5B
Q4 24
$926.1M
Q3 24
$971.7M
Q2 24
$1.3B
$864.6M
Q1 24
Debt / Equity
HCM
HCM
TEM
TEM
Q4 25
0.08×
Q3 25
Q2 25
0.08×
Q1 25
0.11×
Q4 24
Q3 24
Q2 24
0.11×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCM
HCM
TEM
TEM
Operating Cash FlowLast quarter
$8.2M
$-36.8M
Free Cash FlowOCF − Capex
$3.4M
$-41.5M
FCF MarginFCF / Revenue
1.2%
-11.3%
Capex IntensityCapex / Revenue
1.8%
1.3%
Cash ConversionOCF / Net Profit
4.21×
TTM Free Cash FlowTrailing 4 quarters
$-96.2M
$-239.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCM
HCM
TEM
TEM
Q4 25
$8.2M
$-36.8M
Q3 25
$-119.8M
Q2 25
$-72.9M
$44.2M
Q1 25
$40.3M
$-105.6M
Q4 24
Q3 24
$48.7M
Q2 24
$-39.8M
$-97.1M
Q1 24
$-101.4M
Free Cash Flow
HCM
HCM
TEM
TEM
Q4 25
$3.4M
$-41.5M
Q3 25
$-126.5M
Q2 25
$-82.2M
$36.6M
Q1 25
$32.5M
$-107.7M
Q4 24
Q3 24
$48.6M
Q2 24
$-49.9M
$-105.1M
Q1 24
$-107.5M
FCF Margin
HCM
HCM
TEM
TEM
Q4 25
1.2%
-11.3%
Q3 25
-37.9%
Q2 25
-29.6%
11.6%
Q1 25
10.0%
-42.1%
Q4 24
Q3 24
26.9%
Q2 24
-16.3%
-63.3%
Q1 24
-73.7%
Capex Intensity
HCM
HCM
TEM
TEM
Q4 25
1.8%
1.3%
Q3 25
2.0%
Q2 25
3.3%
2.4%
Q1 25
2.4%
0.8%
Q4 24
Q3 24
0.0%
Q2 24
3.3%
4.8%
Q1 24
4.2%
Cash Conversion
HCM
HCM
TEM
TEM
Q4 25
4.21×
Q3 25
Q2 25
-0.16×
Q1 25
3.38×
Q4 24
Q3 24
Q2 24
-1.54×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons